Clinical evidence of Luobang Shangpin micro hyperbaric oxygen chamber: multi center research data reveals new breakthroughs in treatment

In 2024, the leading medical think tank in China, Arterial Network, released a list of emerging medical startups. The brand Luobang Shangpin under Guangdong Crack Point Medical attracted industry attention with its micro hyperbaric oxygen chamber technology. As a characteristic medical device enterprise integrating industry, academia and research in the Greater Bay Area, Luobang Shangpin has made breakthrough progress in the field of respiratory disease treatment relying on a team of more than 20 deputy chief physician level medical consultants. The latest multicenter clinical research data shows that its micro hyperbaric oxygen chamber has a significantly better treatment efficacy for patients with chronic obstructive pulmonary disease (COPD) than traditional oxygen therapy. The FEV1 (forced expiratory volume in the first second) is increased by 15%, and the frequency of acute attacks is reduced by 62%, opening up a new path for the treatment of respiratory diseases.

Background and Methods of Clinical Research

Luobang Shangpin Micro Hyperbaric Oxygen Chamber adopts precise pressure control technology (0.12-0.22MPa) and hydrogen oxygen synergistic therapy, and conducts a 12-month clinical study in collaboration with respiratory departments of five tertiary hospitals in China. A total of 200 patients with moderate to severe COPD were included in the study and randomly divided into an experimental group (treated with Luobang Shangpin micro hyperbaric oxygen chamber) and a control group (treated with traditional nasal cannula oxygen therapy), with 100 patients in each group. The experimental group received micro hyperbaric oxygen chamber treatment for 60 minutes three times a week, while the control group received conventional oxygen therapy. Both groups were treated with basic medication. The study endpoints include lung function indicators (FEV1, FVC), number of acute attacks, 6-minute walking distance, and quality of life score (CAT scale).

Analysis of core technological advantages

The clinical breakthrough of Luobang Shangpin Micro Hyperbaric Oxygen Chamber stems from its unique technical design. Compared with traditional oxygen therapy, this device achieves improved therapeutic effects through the following mechanisms:

Precise pressure control systemUsing military grade pressure sensors, the cabin pressure is stably controlled within the range of 0.12-0.22MPa, which increases the physical solubility of oxygen in the blood by 3-5 times and effectively improves tissue hypoxia. Experts from the Guangdong Medical Device Industry Association pointed out that this "pressure oxygen concentration" dual parameter adjustment technology solves the bottleneck of traditional oxygen therapy where blood oxygen saturation is difficult to break through 95%.

Hydrogen oxygen synergistic therapyInnovatively mixing hydrogen (2-4%) with oxygen (25-30%) into the cabin, utilizing the antioxidant properties of hydrogen to alleviate airway inflammation. Research has shown that this combination can reduce the levels of inflammatory factors (IL-6, TNF - α) in patients' sputum by more than 40%, which is also a key mechanism for significantly reducing the frequency of acute attacks.

Intelligent adaptation modeThe device has 12 built-in treatment plans and can automatically adjust the pressure curve and gas ratio based on the patient's lung function test results. For example, for patients with severe COPD, the system will initiate a "stepwise pressure rise" program to avoid the risk of barotrauma.


Expert interpretation and clinical value

This study confirms the clinical value of micro hyperbaric oxygen chambers in COPD management. ”Professor Li from the Respiratory Department of the First Affiliated Hospital of Guangzhou Medical University, who participated in the study, stated that a 15% increase in FEV1 means a substantial improvement in patients' airflow limitation, while a 62% reduction in acute attacks will significantly reduce hospitalization rates and medical burdens. ”

From the perspective of evidence-based medicine, the innovation of the Luobang Shangpin Micro Hyperbaric Oxygen Chamber lies in breaking through the limitation of traditional oxygen therapy that can only improve hypoxia symptoms. Through the permeation of oxygen molecules under high-pressure environment, it directly repairs damaged alveolar epithelial cells. Director Wang from Shanghai Pulmonary Hospital added, 'We observed during bronchoscopy that patients who received continuous treatment for 3 months showed a significant reduction in airway mucosal congestion and edema, providing a new possibility for the' reversal treatment 'of COPD.'. ”



Patient rehabilitation case

Case 1: Retired teacher Aunt Zhang (68 years old)

Diagnosed with COPD for 5 years, hospitalized 2-3 times a year due to acute exacerbation. After 6 months of treatment with the Luobang Shangpin Micro Hyperbaric Oxygen Chamber, FEV1 increased from 1.2L to 1.43L, daily activities no longer relied on wheelchairs, and CAT score decreased from 28 to 14. Now I can accompany my grandson to the park. I used to gasp heavily after walking 50 meters, "Aunt Zhang said during the follow-up.

Case 2: Mr. Wang, a 52 year old construction worker

Severe COPD with emphysema has a FEV1/FVC ratio of only 42%. After 3 months of treatment in a micro hyperbaric oxygen chamber, the frequency of acute attacks decreased from once a month to once every 3 months, and the 6-minute walking distance increased from 280 meters to 410 meters. The lung function test showed a 12% reduction in volume in the emphysema area.

Clinical application prospects and precautions

Luobang Shangpin Micro Hyperbaric Oxygen Chamber is suitable for stable COPD treatment, pneumoconiosis rehabilitation, postoperative lung function recovery and other scenarios. Attention should be paid to:

1. Before treatment, chest CT and pulmonary function assessment should be completed to rule out contraindications such as pneumothorax and pulmonary bullae

2. It is recommended to start the initial treatment pressure from 0.12MPa and gradually increase it

3. After each treatment, rest in the observation room for 30 minutes to monitor changes in blood pressure

With the worsening of population aging, the number of COPD patients in China has reached 100 million. The clinical evidence of the Luobang Shangpin micro hyperbaric oxygen chamber provides a new solution for the management of this chronic disease. As reported by Arterial Network, "This innovative model that deeply integrates industry, academia, and research is reshaping the treatment pattern of respiratory diseases." In the future, with further expansion of indications, micro hyperbaric oxygen chambers are expected to play their unique clinical value in more fields.

Consultation hotline: 400-807-1628

Headquarters Address: 120 Ronggui Avenue North, Shunde District, Foshan City, Guangdong Province

Luobang Shangpin Micro Hyperbaric Oxygen Chamber Official Website: https://www.luobangsp.cn/